Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 733

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance

Open access
Moore, Matthew R, Link-Gelles, Ruth, Schaffner, William, Lynfield, Ruth, Lexau, Catherine, Bennett, Nancy M, Petit, Susan, Zansky, Shelley M, Harrison, Lee H, Reingold, Arthur, Miller, Lisa, Scherzinger, Karen, Thomas, Ann, Farley, Monica M, Zell, Elizabeth R, Taylor, Thomas H, Pondo, Tracy, Rodgers, Loren, McGee, Lesley, Beall, Bernard, Jorgensen, James H, Whitney, Cynthia G·2015·The Lancet Infectious Diseases

Abstract

SUMMARY Background In 2000, 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in the U.S. and resulted in dramatic reductions in invasive pneumococcal disease (IPD) and modest increases in non-PCV7-type IPD. In 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) replaced PCV7 in the U.S. immunization schedule. We evaluated the effect of PCV13 use in children on IPD in children and adults in the U.S. Methods We used laboratory- and population-based data on incidence of IPD from CDC’s Emerging Infections Program / Active Bacterial Core surveillance in a time-series model to estimate the impact of vaccination. Cases of IPD during July 2004–June 2013 were classified as being caused by the PCV13 serotypes against which PCV7 has no effect (PCV13/nonPCV7). Findings Compared with incidence expected among children <5 years old if PCV7 alone had been continued, incidence of IPD overall and IPD caused by PCV13/nonPCV7 serotypes declined by 64% (95% interval estimate [IE] 59–68 %) and 93% (95%IE 91–94), respectively, by July 2012–June 2013. Among adults, incidence of IPD overall and PCV13/nonPCV7-type IPD also declined by 12–32% and 58–72%, respectively, depending on age. In all age groups, reductions were driven principally by changes in incidence of serotypes 19A and 7F. We estimate that over 30,000 cases of IPD and 3,000 deaths were averted in the first 3 years following PCV13 introduction. Interpretation PCV13 has reduced IPD among all ages when used routinely in children in the U.S. Serotypes 19A and 7F, which emerged after PCV7 introduction, have been effectively controlled.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1473-3099(14)71081-3

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 733

Metadata

Authors
Moore, M. R., Link-Gelles, R., Schaffner, W., Lynfield, R., Lexau, C., Bennett, N. M., Petit, S., Zansky, S. M., Harrison, L. H., Reingold, A., Miller, L., Scherzinger, K., Thomas, A., Farley, M. M., Zell, E. R., Taylor, T. H., Pondo, T., Rodgers, L., McGee, L., Beall, B., Jorgensen, J. H., & Whitney, C. G.
Venue
The Lancet Infectious Diseases
Publisher
Elsevier BV
Published
2015-03
Volume
15
Issue
3
Pages
301-309
ISSN
1473-3099 (ISSN-L)
OpenAlex
W1963985157
Cited by
733
References
29
FWCI
72.24
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. https://app.cochat.ai/papers/10.1016/s1473-3099(14)71081-3
The paper
Moore, M. R., Link-Gelles, R., Schaffner, W., Lynfield, R., Lexau, C., Bennett, N. M., Petit, S., Zansky, S. M., Harrison, L. H., Reingold, A., Miller, L., Scherzinger, K., Thomas, A., Farley, M. M., Zell, E. R., Taylor, T. H., Pondo, T., Rodgers, L., McGee, L., . . . Whitney, C. G. (2015). Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(14)71081-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.